Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655550 | PMC |
| http://dx.doi.org/10.1038/s41408-024-01200-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
Blood Cancer J
December 2024
Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Paris, France.
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma.
Ann Pharmacother
May 2025
Union University College of Pharmacy, Jackson, TN, USA.
Objective: To review the therapeutic profile of elranatamab, a novel bispecific T-cell-redirecting therapy, in treating relapsed or refractory (R/R) multiple myeloma (MM).
Data Sources: A PubMed search was conducted for English-language articles published from January 2000 through June 2024, using the search terms: , and "" Additional data were obtained from ClinicalTrials.gov and other pertinent publications and meeting abstracts.
[Elranatamab monotherapy in multiple myeloma after at least three prior treatments].
Bull Cancer
October 2024
EA 7453 CHELTER, service d'hématologie clinique adulte et de thérapie cellulaire, CHU Estaing, université Clermont Auvergne, Clermont-Ferrand, France. Electronic address:
A tertiary care centre experience with Elranatamab: A report of three cases.
Leuk Res Rep
June 2024
Department of Haemat-oncology, Rajiv Gandhi cancer institute and research centre, New Delhi, India.
Article Synopsis
- The introduction of new treatments like proteasome inhibitors and monoclonal antibodies has significantly improved life expectancy for multiple myeloma patients, but there's a need for better therapies, particularly for those with triple-class refractory disease.
- Elranatamab, a bispecific antibody, is commonly used in India for treating this condition, though data on its effectiveness in real-world settings is lacking.
- In a small case report of three patients receiving elranatamab monotherapy, common side effects included mild cytokine release syndrome and cytopenias, with one patient experiencing severe neurological toxicity, highlighting the need for ongoing assessment of treatment safety and efficacy.
Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.
Jpn J Clin Oncol
September 2024
Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Article Synopsis
- The study focuses on the efficacy and safety of elranatamab, a bispecific antibody treatment, for Japanese patients with relapsed or refractory multiple myeloma (RRMM).
- Results showed a 50% objective response rate in one study and 58.3% in another, with no dose-limiting toxicities observed.
- Although all patients experienced treatment-related adverse events, there were no new safety concerns, suggesting elranatamab is a viable option for RRMM patients in Japan.